Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06095765
Other study ID # ONZ-2023-0237
Secondary ID KCE-INV-21-13242
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 29, 2024
Est. completion date March 1, 2028

Study information

Verified date March 2024
Source AZ Sint-Jan AV
Contact Lisette Van Hove
Phone +32 50 45 39 07
Email Lisette.VanHove@azsintjan.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after treatment with PCI, compared with placebo in combination with optimal standard treatment. More specifically, we aim to investigate the benefits of a daily low dose of colchicine in patients with coronary artery disease after treatment with PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in coronary artery disease, and to identify a subgroup of patients with CAD who are at increased risk for cardiovascular events and could benefit most from colchicine.


Description:

This is a prospective, randomised, double-blind, multicenter, placebo-controlled phase III pragmatic superiority trial comparing colchicine 0.5 mg with placebo administered orally once-daily in up to 2770 participants with CAD treated with PCI. Participants will be randomised in a 1:1 ratio to receive either colchicine 0.5 mg or placebo as an adjunct to standard of care. The trial is event driven with trial closure being performed when the targeted number of 566 primary endpoint events has been reached. Participants will be seen by the site staff 1 month after randomisation and thereafter every 12 months as per standard of care (SOC) and for IMP dispense and compliance, completing questionnaires and outcome event assessment until end of study. After the first month, a telephone visit will be scheduled every 6 months in between two standard of care on-site visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 2770
Est. completion date March 1, 2028
Est. primary completion date November 1, 2027
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: 1. Age =45 years. 2. Coronary artery disease treated with PCI and optimal medical therapy, with at least one additional risk factor (based on SMART): 1. Age = year 2. Diabetes mellitus, on treatment or new diagnosis with HbA1c =6.5% 3. Current smoking 4. Treated hypertension or lood pressure systolic = 4 mmHg or diastolic = mmHg 5. Total cholesterol >240 mg/dl untreated, or treated LDL >70 mg/dl 6. HDL <40 mg/dl 7. hsCRP >2 mg/L AND chronic coronary syndrome (CCS) 8. eGFR <60 ml/min (MDRD) 9. history of vascular disease: - CAD (PCI prior to index, CABG, MI) - stroke (ischemic or hemorrhagic) - carotid artery revascularisation - PAD (revascularisation, ABI <0.85 at rest, amputation due to atherosclerotic disease) - AAA (repair, distal aortic anteroposterior diameter >3.0cm) 3. Able to be enrolled/randomized between 2 hour and 5 days post PCI. 4. Written informed consent. Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or of childbearing potential who are not using an effective method of contraception. Or women who intend to donate oocytes. 2. Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm. 3. Any contraindication or known intolerance to colchicine. 4. Chronic use of -or need for- colchicine. 5. Auto-immune disease or other condition requiring current or planned chronic systemic steroids, immunosuppressant or biologic drug targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab etc.). 6. Creatinine clearance <30 mL/min/1.73 m2. 7. Cirrhosis Child-Pugh stadium B and C, or acute severe liver disease 8. Neuromuscular disease or non-transient CK levels > 5 x ULN (unless due to MI). 9. History of cancer or lymphoproliferative disease within the last 3 years, other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, or localized cervix carcinoma in situ. 10. Current or planned use of any strong inhibitor of CYP3A4 or p-glycoprotein: macrolide antibiotics (clarithromycin, telithromycin), azole antifungal agents (ketoconazole, voriconazole, fluconazole, itraconazole), cyclosporine, HIV medication (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir). 11. Chronic diarrhea, or inflammatory owel disease (Crohn's disease or ulcerative colitis). 12. Drug or alcohol abuse. 13. Planned cardiovascular intervention known on the day of screening. 14. Currently enrolled in another investigational trial. 15. Considered to be an unsuitable candidate by the investigator.

Study Design


Intervention

Drug:
Colchicine 0.5 MG Oral Tablet
Oral intake of 0.5 mg colchicine once daily
Placebo
Oral intake of matching placebo once daily

Locations

Country Name City State
Belgium Algemeen Stedelijk Ziekenhuis Campus Aalst Aalst
Belgium Het Ziekenhuisnetwerk Antwerpen Antwerpen
Belgium Universitair Ziekenhuis Antwerpen Antwerpen
Belgium Imelda Bonheiden
Belgium AZ Sint-Jan Brugge-Oostende AV Brugge
Belgium Grand Hôpital de Charleroi Charleroi
Belgium Humani Charleroi Charleroi
Belgium Ziekenhuis Oost Limburg Genk
Belgium AZ Sint-Lucas & Volkskliniek Gent
Belgium Universitair Ziekenhuis Gent Gent
Belgium Jessa Ziekenhuis Hasselt
Belgium Algemeen Ziekenhuis Groeninge Kortrijk
Belgium UZ Leuven Leuven
Belgium Centre Hospitalier Regional De La Citadelle Liège
Belgium Clinique Saint-Luc Bouge Namur
Belgium AZ Delta Roeselare
Belgium AZ Turnhout Turnhout
Belgium Cliniques Universitaires Saint-Luc Woluwe-Saint-Lambert
Belgium UCL Mont-Godinne Yvoir

Sponsors (3)

Lead Sponsor Collaborator
AZ Sint-Jan AV Belgium Health Care Knowledge Centre, University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

References & Publications (6)

Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook NR, van der Graaf Y; SMART Study Group. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013 Jun;99(12):866-72. doi: 10.1136/heartjnl-2013-303640. Epub 2013 Apr 10. — View Citation

Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, Thompson PL, Budgeon C, Tijssen JGP, Cornel JH. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021 Jul 21;42(28):2765-2775. doi: 10.1093/eurheartj/ehab115. Erratum In: Eur Heart J. 2021 May 23;: — View Citation

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19. — View Citation

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. — View Citation

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. — View Citation

Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Hengel C, Asrress K, Freeman M, Amerena J, Wilson A, Layland J. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020 Nov 17;142(20):1890-1900. doi: 10.1161/CIRCULATIONAHA.120.050771. Epub 2020 Aug 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change from randomisation to year 1 (and year 2 if available): in hsCRP as a measure of Inflammation. Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
(high sensitivity) C-reactive protein (mg/dl)
24 months
Other Change from randomisation to year 1 (and year 2 if available): in white blood cell count as a measure of Inflammation. Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
white blood cell count (/µl)
24 months
Other Change from randomisation to year 1 (and year 2 if available) in total cholesterol. Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
total cholesterol (mg/dl)
24 months
Other Change from randomisation to year 1 (and year 2 if available) in low density lipoprotein. Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
low density lipoprotein (LDL) (mg/dl)
24 months
Other Change from randomisation to year 1 (and year 2 if available) in high density lipoprotein . Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
high density lipoprotein (HDL) (mg/dl)
24 months
Other Change from randomisation to year 1 (and year 2 if available) in triglycerides. Change from randomisation to year 1 (and year 2 if available) in blood lab results from:
triglycerides (mg/dl)
24 months
Other Change from randomisation to year 1 (and year 2 if available) in kidney function. Change from randomisation to year 1 (and year 2 if available) in blood lab results from: estimated glomerular filtration rate (ml/min) 24 months
Primary Time from randomisation to first occurrence of a composite endpoint consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation. 44 months
Secondary Time from randomisation to first occurrence of a composite of specific cardiovascular endpoints Time from randomisation to first occurrence of a composite of: cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke or coronary revascularisation 44 months
Secondary Time from randomisation to first occurrence of a composite of hard endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke 44 months
Secondary Time from randomisation to first occurrence of breakdown components of primary endpoint and atherosclerosis-related diseases Time from randomisation to first occurrence of: all-cause death, cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, coronary revascularisation, ischemia driven coronary revascularisation, stent thrombosis, peripheral artery revascularisation, transient ischemic attack (TIA) treated with carotid revascularisation 44 months
Secondary Time from randomisation to occurrence of first as well as recurrent endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation. 44 months
Secondary Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Angina Frequency scale Change from randomisation to year 1 and to end of study of participants reported outcomes:
Seattle Angina Questionnaire (SAQ) Angina Frequency Scale: categorizes angina (chest pain) frequency as following: daily angina (score = 0-30), weekly angina (score = 31-60), monthly angina (score = 61-99), and no angina (score = 100). Higher score indicates better outcome.
44 months
Secondary Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Dyspnea Change from randomisation to year 1 and to end of study of participants reported outcomes:
Dyspnea (Rose Dyspnea Scale): a four-item questionnaire that assesses a patients' dyspnea level with common activities. One point is assigned to each activity associated with dyspnea. Scores range from 0 to 4. Higher score indicates worse outcome.
44 months
Secondary Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Depression. Change from randomisation to year 1 and to end of study of participants reported outcomes:
Depression (Patient Health Questionnaire PHQ-2): inquires about the frequency of depressed mood and anhedonia. Scores range from 0 to 6. Higher score indicates worse outcome.
44 months
Secondary Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Health-related quality of life. EuroQol five dimensions five level (EQ-5D-5L): consists of a descriptive system of self-perceived health status along fve dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (VAS) which provides a self-rating of the general health status on a scale from 0 (worst imaginable state of health) to 100 (best imaginable state of health). 44 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A